Business- Page 68

Former Qualtrics Chief Transformation Officer joins the AvePoint Executive Leadership Team to deepen customer value and accelerate growth as enterprises scale AI with trust JERSEY CITY, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE)

Conditional agreement covering 52 wells could generate more than $2 million in annual service revenue for Direct Midstream at targeted operating levels Dallas, TX, Nov. 04, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc.

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with relapsed/refractory monocytic AML

Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID)

FALLS CHURCH, Va., Nov. 04, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) will participate in the Baird 2026 Global Industrial Conference on Wednesday, November 11. Kathy Warden, chair, chief executive

14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show

Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R

Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib plus venetoclax